TY - JOUR
T1 - Report of the 23rd nationwide follow-up survey of primary liver cancer in Japan (2014–2015)
AU - Iijima, Hiroko
AU - Kudo, Masatoshi
AU - Kubo, Shoji
AU - Kurosaki, Masayuki
AU - Sakamoto, Michiie
AU - Shiina, Shuichiro
AU - Tateishi, Ryosuke
AU - Osamu, Nakashima
AU - Fukumoto, Takumi
AU - Matsuyama, Yutaka
AU - Murakami, Takamichi
AU - Takahashi, Arata
AU - Miyata, Hiroaki
AU - Kokudo, Norihiro
N1 - Publisher Copyright:
© 2023 The Authors. Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology.
PY - 2023/10
Y1 - 2023/10
N2 - For the 23rd Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 20 889 newly registered patients and 42 274 previously registered follow-up patients were compiled from 516 institutions over a 2-year period from January 1, 2014 to December 31, 2015. Basic statistics compiled for patients newly registered in the 23rd survey were cause of death, past medical history, clinical diagnosis, imaging diagnosis, treatment-related factors, pathological diagnosis, recurrence status, and autopsy findings. Compared with the previous 22nd survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, had more female patients, had more patients with non-B non-C HCC, had smaller tumor diameter, and was more frequently treated with hepatectomy. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma, and combined hepatocellular cholangiocarcinoma (combined HCC and intrahepatic cholangiocarcinoma) by treatment type and background characteristics for patients newly registered between 2004 and 2015 whose final outcome was survival or death. The median overall survival and cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter, Child–Pugh grade, or albumin-bilirubin grade) and by treatment type (hepatectomy, radiofrequency ablation therapy, transcatheter arterial chemoembolization, hepatic arterial infusion chemotherapy, and systemic therapy). The same values were also calculated according to registration date by dividing patients newly registered between 1978 and 2015 into five time period groups. The data obtained from this nationwide follow-up survey are expected to contribute to advancing clinical research and treatment of primary liver cancer in the world.
AB - For the 23rd Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 20 889 newly registered patients and 42 274 previously registered follow-up patients were compiled from 516 institutions over a 2-year period from January 1, 2014 to December 31, 2015. Basic statistics compiled for patients newly registered in the 23rd survey were cause of death, past medical history, clinical diagnosis, imaging diagnosis, treatment-related factors, pathological diagnosis, recurrence status, and autopsy findings. Compared with the previous 22nd survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, had more female patients, had more patients with non-B non-C HCC, had smaller tumor diameter, and was more frequently treated with hepatectomy. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma, and combined hepatocellular cholangiocarcinoma (combined HCC and intrahepatic cholangiocarcinoma) by treatment type and background characteristics for patients newly registered between 2004 and 2015 whose final outcome was survival or death. The median overall survival and cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter, Child–Pugh grade, or albumin-bilirubin grade) and by treatment type (hepatectomy, radiofrequency ablation therapy, transcatheter arterial chemoembolization, hepatic arterial infusion chemotherapy, and systemic therapy). The same values were also calculated according to registration date by dividing patients newly registered between 1978 and 2015 into five time period groups. The data obtained from this nationwide follow-up survey are expected to contribute to advancing clinical research and treatment of primary liver cancer in the world.
KW - Japan Liver Cancer Association
KW - combined hepatocellular cholangiocarcinoma
KW - cumulative survival rate
KW - hepatocellular carcinoma
KW - intrahepatic cholangiocarcinoma
KW - nationwide follow-up survey
KW - nationwide survey
UR - http://www.scopus.com/inward/record.url?scp=85169788423&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85169788423&partnerID=8YFLogxK
U2 - 10.1111/hepr.13953
DO - 10.1111/hepr.13953
M3 - Article
AN - SCOPUS:85169788423
SN - 1386-6346
VL - 53
SP - 895
EP - 959
JO - Hepatology Research
JF - Hepatology Research
IS - 10
ER -